**SUPPLEMENTARY TABLE 1.** Spearman correlations between the changes from baseline at Week 12 in key secondary efficacy outcomes (FAS)

<table>
<thead>
<tr>
<th>Treatment arm</th>
<th>Baseline</th>
<th>Study eye</th>
<th>Fellow eye</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Change from baseline at Week 12</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>BCVA score r (P-value)</td>
<td>Central subfield retinal thickness r (P-value)</td>
</tr>
<tr>
<td><strong>PF-04634817</strong></td>
<td>200 mg QD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BCVA score</td>
<td>–0.181 (0.1135)</td>
<td>0.128 (0.2647)</td>
<td>–0.161 (0.1594)</td>
</tr>
<tr>
<td>Central subfield retinal thickness</td>
<td>–0.302 (0.0072)</td>
<td>–0.288 (0.0105)</td>
<td>0.177 (0.1206)</td>
</tr>
<tr>
<td>Area of vascular leakage</td>
<td>0.131 (0.2530)</td>
<td>–0.009 (0.9407)</td>
<td>–0.072 (0.5331)</td>
</tr>
<tr>
<td>HbA1c</td>
<td>0.040 (0.7301)</td>
<td>0.340 (0.0023)</td>
<td>0.097 (0.3984)</td>
</tr>
<tr>
<td>Serum MCP-1</td>
<td>–0.181 (0.1126)</td>
<td>–0.021 (0.8585)</td>
<td>–0.183 (–0.1088)</td>
</tr>
<tr>
<td>eGFR\textsubscript{EPI}</td>
<td>0.041 (0.7188)</td>
<td>0.093 (0.4160)</td>
<td>0.171 (0.1337)</td>
</tr>
<tr>
<td>Steps of diabetic retinopathy*</td>
<td>0.231 (0.0418)</td>
<td>–0.012 (0.9146)</td>
<td>–0.018 (0.8737)</td>
</tr>
<tr>
<td><strong>Ranibizumab</strong></td>
<td>0.3/0.5 mg plus placebo QD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BCVA score</td>
<td>–0.329 (0.0051)</td>
<td>0.305 (0.0097)</td>
<td>–0.145 (0.2261)</td>
</tr>
<tr>
<td>Central subfield retinal thickness</td>
<td>0.354 (0.0025)</td>
<td>–0.583 (&lt;0.0001)</td>
<td>–0.042 (0.7268)</td>
</tr>
<tr>
<td></td>
<td>-0.038 (0.7522)</td>
<td>-0.007 (0.9517)</td>
<td>-0.367 (0.0016)</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-----------------</td>
<td>-----------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>Area of vascular leakage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HbA1c</td>
<td>0.035 (0.7697)</td>
<td>0.144 (0.2297)</td>
<td>-0.006 (0.9629)</td>
</tr>
<tr>
<td>Serum MCP-1</td>
<td>0.102 (0.3982)</td>
<td>0.006 (0.9588)</td>
<td>-0.034 (0.7815)</td>
</tr>
<tr>
<td>eGFR_EPI</td>
<td>0.163 (0.1755)</td>
<td>-0.155 (0.1969)</td>
<td>0.044 (0.7152)</td>
</tr>
<tr>
<td>Steps of diabetic retinopathy*</td>
<td>-0.085 (0.4790)</td>
<td>-0.003 (0.9792)</td>
<td>0.046 (0.7016)</td>
</tr>
</tbody>
</table>

*ETDRS severity scale

Baseline defined as the most recent non-missing value prior to dosing.

*P*-values associated with Spearman correlation coefficient (r). Significant *P*-values in bold.

BCVA, best corrected visual acuity; eGFR_EPI, estimated glomerular filtration rate calculated using Chronic Kidney Disease Epidemiology Collaboration (CKD_EPI) formula; ETDRS, Early Treatment Diabetic Retinopathy Study; FAS, full analysis set; HbA1c, hemoglobin A1c; MCP-1, monocyte chemoattractant protein 1; QD, once-daily; r, Spearman correlation coefficient.

**Reference**